Abstract
In this issue of Blood, Barz et al identified NT5C2 thiopurine resistance mutations in 16% of children with relapsed B-cell acute lymphoblastic leukemia (B-ALL). Despite the fact that most of the mutations were subclonal, their presence was associated with an inferior outcome. Strikingly, NT5C2-mutated cells were sensitive to relapse therapy, suggesting a complex association between NT5C2 mutations and the poor prognosis of relapsed ALL.
Original language | English |
---|---|
Pages (from-to) | 886-887 |
Number of pages | 2 |
Journal | Blood |
Volume | 135 |
Issue number | 12 |
DOIs | |
State | Published - 19 Mar 2020 |
Externally published | Yes |